Click on a filter below to refine your search. Remove a filter to broaden your search.
Risks for new-onset psychiatric diagnoses and anxiety disorders, but not mood disorders, increased in the early postacute phase.
However, for all ages, vaccine effectiveness against severe COVID-19 was high overall, at 90% five months or longer after two doses.
No increase in vaccine uptake was seen for individuals receiving text message versus phone calls or for behaviorally informed message content.
The authors say that the review findings are limited by heterogenous definitions of long COVID in published studies.
Compared with placebo, normalization of C-reactive protein and oxygen saturation was faster, with improvements seen on day 3 of treatment.
SARS-CoV-2 vaccination appears to have no positive or negative impact on cognitive function or fatigue.
Individuals with breakthrough infection have an increased risk for death and postacute sequelae compared with contemporary controls.
Persisting evidence of cardio-renal involvement and hemostasis pathway activation was reported at 28 to 60 days after discharge.
Most SARS-CoV-2 infections are not asymptomatic; those with asymptomatic infections are less infectious.
No specific causes of symptoms of postacute sequelae of SARS-CoV-2 infection were identified.